Neumora Therapeutics (NMRA) EBITDA (2022 - 2026)

Neumora Therapeutics has reported EBITDA for 5 years, with the latest figure at -$53.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 21.45% year-over-year to -$53.5 million; the trailing twelve-month figure through Mar 2026 stood at -$222.4 million (up 13.77% YoY), and the FY2025 full-year result was -$237.0 million, up 2.73% from the prior year.
• EBITDA for Q1 2026 stood at -$53.5 million, up from -$59.5 million in the prior quarter.
• The five-year high for EBITDA was -$27.8 million in Q4 2022, with the low at -$108.5 million in Q4 2023.
• Average EBITDA over 5 years is -$55.1 million, with a median of -$53.8 million recorded in 2024.
• Year-over-year, EBITDA tumbled 290.75% in 2023 and soared 45.75% in 2024.
• Tracing NMRA's EBITDA over 5 years: stood at -$27.8 million in 2022, then plunged by 290.75% to -$108.5 million in 2023, then soared by 45.75% to -$58.9 million in 2024, then decreased by 1.01% to -$59.5 million in 2025, then advanced by 10.09% to -$53.5 million in 2026.
• The last three EBITDA figures came in at -$53.5 million (Q1 2026), -$59.5 million (Q4 2025), and -$56.7 million (Q3 2025), per Business Quant data.

Peer Comparison